Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New Press Release - Theralase(R) Provides Update on Bladder Cancer Clinical Study

<< Previous

Bullboard Posts

Next >>

Comment by N0taP00pon Oct 16, 2023 11:54pm

214 Views

Post# 35686558

RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Theralase(R) Provides Update on Bladder Cancer Clinical Study

@999: Unless people are a bit dense, it is easy to see that the "fear being injected" (that you allege) is from people who have been invested for long and seen the dilution and delay movie play on repeat. We'll see if your prediction of $4 by this year plays out as well as January warrants being exercised at 50 cents. I'm sticking with the Nov/Dec dilution story and BTD early next year. May you win this one.

99942Apophis wrote:
StevenBirch wrote: Yes an update so soon? The FDA requested a resubmission of the pre-BTD so you would think that if they clean up a couple of things that maybe THEY think BTD is in the offing. And Arkady says "This ACT technology...will be very attractive to patients & uro-oncologists (obvious) AND the insurance companies that insure these patients".

Every update exudes more confidence including their ability to commercialize their technology!

Oilminerdeluxe wrote: Something must be behind this release. I didn't think we would see anything until the next Q report. Always happy too see updates. Perhaps JV negotiations as you say, or a boring but needed PP? We will see. That BTD would be soooo nice to have in the pocket. Perhaps the pre-application thing is very close now at least.

Thank you StevenBirch that is more than likely one of the points outlined by the FDA what we saw and read in today's update. Exactly a clear patient update with current data numbers for the new Pre-BTD, sometimes people just can't see what's right there in front of them. My bet today's update was part of the FDA’s request.
Might I also say to those who are trying to inject fear by suggesting another financial raise that in any business strategy once they start releasing many News Releases in short time lapses its a buildup to very powerful announcements. No financial needs currently as the January 9th 50 cent warrants will give them 2 million into their coffers. The way I see it volume will increase progressively over the next few weeks and months along with the share price & warrants to $3 -$5 by 2023 year end.